| abstract |
Ribavirin® is administered to a patient in a dosage range which is effective tonmodulate lymphokine expression in activated T cells. In particular, Ribavirin® is used tonsuppress Th2-mediated T cell responses and promote Th1-mediated T cell response. Innother apsects of the invention, one or more Ribavirin® analogs are administered to anpatient in a dosage range which is effective to modulate lymphokine expression innactivated T cells. The Ribavirin® analog(s) may be used to suppress or enhance Th1 ornTh2-mediated T cell responses. |